4 IU/mL) except for 1 donor (1.33×10 8 IU/mL). All the isolated B19V DNAs from 6 donors were identified as genotype I. Nine out of 10 B19V DNA positive donors also possessed anti-B19V IgG only or IgG and IgM. The prevalence of anti-B19V IgG was 60.1% (558/928).
INTRODUCTION
The safety of plasma derivatives has been reinforced with more stringent donor questionnaires, implementation of nucleic acid testing (NAT), and treatment of pathogen inactivation and elimination (PI/PE) by plasma fractionation. However, human parvovirus B19 (B19V) transfusion-transmitted infection cases associated with plasma derivatives have been occasionally reported [1] [2] [3] , particularly in patients with increased risks of infection, such as infants and immunocompromised or pregnant patients.
The prevalence of B19V DNA among blood donors has been reported as 0.003-0.9% [4] and the anti-B19V antibody frequency as 30-75% globally [5] [6] [7] [8] . The US Food and Drug administration (FDA) guidelines and the European regulatory requirements recommend that the viral load of B19V in the manufacturing of pooled plasma should not exceed 10 4 IU/mL [5] . The Japanese Red Cross has been screening B19V antigen since 1985 [6] and the German Red
Cross implemented B19V mini pool NAT (96 pool) for blood donor screening in 2000 [7] . Additionally, many other Background : To ensure the safety of plasma derivatives, some countries have been screening for the human parvovirus B19 (B19V) antigen or DNA in blood donors. We investigated the prevalence of B19V DNA and anti-B19V antibodies in Korean plasmapheresis donors to evaluate the necessity of B19V DNA screening test.
Methods : Plasma samples were collected between March and July 2008 from 10,032 plasmapheresis donors. The B19V DNA test was performed using the LightCycler 2.0 (Roche, Germany) with quantification kits. Anti-B19V IgM and IgG were tested in 928 randomly selected samples from the 10,032 donors using recomWell Parvovirus B19 ELISA IgM, IgG assay (Mikrogen, Germany). RecomLine Parvovirus B19 LIA IgG, IgM assay (Mikrogen, Germany) was used to analyze the epitopes of antibodies in donors showing positive results for B19V DNA and anti-B19V antibodies. DNA sequencing was performed to identify the genotypes.
Results : The prevalence of B19V DNA was 0.1% (10/10,032). Virus titers in B19V DNA positive donors were less than 10 5 IU/mL (range: 2.7×10
countries have been implementing B19V large pool NAT for pooled plasma samples and products that are manufactured [8] .
In Korea, there is no regulation to ensure the safety of plasma derivatives for B19V. The Korean Food and Drug
Administration has been concerned with establishing new guidelines to limit B19V contamination in pooled plasma samples and manufacturing products. Some Korean authors have reported the occurence of B19V antigen in plasmapheresis donors [9] and anti-B19V antibody in Korean patients [10] . We investigated the prevalence of B19V DNA in Korean plasmapheresis donors to evaluate the necessity of B19V screening. 
MATERIALS AND METHODS

B19V DNA test
Anti-B19V antibody immunoassay
We randomly tested 928 samples from 10,032 donors for were interpreted using the criteria outlined in the package insert from the manufacturer (U/mL sample >24, positive; U/mL sample <20, negative; 20≤ U/mL sample ≤24, borderline).
Retrospective and follow-up tests
To The purified PCR products were sequenced using a Big [11, 12] .
RESULTS
The prevalence of B19V DNA
Ten out of 10,032 plasmapheresis donors showed positive results in B19V DNA test (0.1%). The titers of B19V DNA in 9 of 10 donors were low (range, 27-3.2×10 4 IU/ mL), and 1 donor showed high virus titer (1.33×10 8 IU/ mL) ( Table 2 ). 
The prevalence of anti-B19V antibodies
Retrospective and follow-up study
The results of the retrospective and follow-up test are shown in Table 5 . B19V DNA titers reduced at the follow- (Table 4 ).
B19V sequence analysis
The genotypes of B19V DNA taken from the 6 donors were identified as the G1 genotype.
DISCUSSION
The safety of plasma derivatives with regard to B19V
has been a major concern to date. Contamination with a high titer of B19V can cause serious problems in patients with an increased risk of infection such as infants and those who are immunocompromised or pregnant. There were some reports of transfusion-transmitted B19V infec- Table 4 . The results of the confirmatory test for the positive donors in both anti-B19V and B19V NAT tion through the use of tainted plasma products [13, 14] .
In our study, the prevalence of B19V DNA in healthy Korean plasmapheresis donors was 0.1%, which was not high compared with that of other countries such as United States (0.83-0.88%), and Germany and Austria (0.27%) [7, 15] .
Additionally, the donors had low viral loads (range, 10 2 -10 3 IU/mL), except for one donor. These results are consistent with those of previous reports [15] .
Recently, the significance of the neutralizing effect of anti-B19V IgG has been considered in B19V infection. The anti-B19V IgG in donated blood or recipients can neutralize the virus and prevent B19V infection. Some reports indicate that 11 U/mL of anti-B19V antibody can neutralize 4.3 log of B19V DNA [16] .
Kleinman et al. [17] reported that minimum infectious doses of B19V were 2×10 4 IU/mL (in the coagulation factor) or 10 7 IU/mL (in the other plasma products) for recipients who did not possess neutralizing antibodies. They also insisted that the blood products containing virus titers below 10 4 IU/mL were not infectious [17] . � U/mL sample >24, positive; U/mL sample <20, negative; ≥20 U/mL sample ≤24, borderline. Abbreviations: B19V, human parvovirus B19; ND, not done. Table 5 . B19V DNA and anti-B19V antibodies in retrospective and follow-up specimens VP2) in the blood products. GRCBC reported that 75% of the B19V DNA negative donors possessed neutralizing antibodies, which could protect against B19V infection.
In our study, 90% of the B19V DNA positive plasmapheresis donors and 60% of the 928 randomly selected plasmapheresis donors possessed anti-B19V IgG. However, the blood components containing high titers of B19V
(1. IgG. Japanese groups [18, 19] have reported that most of the transfusion transmitted B19V infected patients show only mild symptoms such as a fever or rash.
Recently, new pathogen elimination techniques such as nanofiltration (20-35 nm pore size) have been introduced and the Japanese Red Cross has been using this method during fractionation.
In conclusion, the prevalence of the B19V DNA in Korean plasmapheresis donors was not high and more than 60% of the plasmapheresis donors possessed neutralizing anti-B19V antibodies, thereby suggesting that the possibility of transfusion transmitted B19V infection in Korea is not serious. Therefore, the implementation of B19V DNA screening for all blood donors does not seem to be warranted at this time.
